Knight Therapeutics (FRA:04K) PE Ratio without NRI: 147.56 (As of Jul. 04, 2026) — 94% Above Median


FRA:04K Knight Therapeutics Inc FRA:04K
73 GF Score
Price €6.05
GF Value €5.30
! 6 Warning Signs
View Full Analysis

What is Knight Therapeutics PE Ratio without NRI?

Knight Therapeutics FRA:04K 73 PE Ratio without NRI is 147.56 as of Jul. 04, 2026, which is 94% above its 10-year median of 76.03. GuruFocus rates FRA:04K with a GF Score™ of 73/100 and a GF Value™ of €5.30. The stock has 6 warning signs investors should review. Among 654 Drug Manufacturers companies, Knight Therapeutics ranks worse than 94.8% on this metric.

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. As of today (2026-07-04), Knight Therapeutics's share price is €6.05. Knight Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.04. Therefore, Knight Therapeutics's PE Ratio without NRI for today is 147.56.

During the past 13 years, Knight Therapeutics's highest PE Ratio without NRI was 4025.00. The lowest was 42.79. And the median was 76.03.

Knight Therapeutics's EPS without NRI for the three months ended in Mar. 2026 was €0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 was €0.04.

As of today (2026-07-04), Knight Therapeutics's share price is €6.05. Knight Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03. Therefore, Knight Therapeutics's PE Ratio (TTM) for today is 195.16.

Warning Sign:

Knight Therapeutics Inc stock PE Ratio (=189) is close to 10-year high of 189.6.

During the past years, Knight Therapeutics's highest PE Ratio (TTM) was 197.15. The lowest was 11.11. And the median was 55.98.

Knight Therapeutics's EPS (Diluted) for the three months ended in Mar. 2026 was €0.08. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03.

Knight Therapeutics's EPS (Basic) for the three months ended in Mar. 2026 was €0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was €0.03.


Knight Therapeutics  (FRA:04K) PE Ratio without NRI Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio without NRI measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.


Knight Therapeutics PE Ratio without NRI Related Terms


Knight Therapeutics PE Ratio without NRI Historical Data

* Premium members only.

The historical data trend for Knight Therapeutics's PE Ratio without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Knight Therapeutics PE Ratio without NRI Chart

Knight Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PE Ratio without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 139.47 At Loss 82.38 56.81 At Loss

Knight Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PE Ratio without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 227.78 At Loss At Loss At Loss 114.00

FRA:04K vs ZTS, UTHR: PE Ratio without NRI Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Knight Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Knight Therapeutics PE Ratio without NRI vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Knight Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Knight Therapeutics's PE Ratio without NRI falls into.


FRA:04K
73GF Score
Knight Therapeutics Inc FRA:04K
PE Ratio without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Knight Therapeutics PE Ratio without NRI Calculation

The PE Ratio without NRI, or P/E Ratio without non-recurring items, is a financial ratio used to compare a company's market price to its EPS without NRI. Regular PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.

Knight Therapeutics's PE Ratio without NRI for today is calculated as

PE Ratio without NRI=Share Price/ EPS without NRI
=6.05/0.041
=147.56

Knight Therapeutics's Share Price of today is €6.05.
Knight Therapeutics's EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.04.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months.

For Forward PE Ratio, the earnings are the expected earnings for the next twelve months.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.

Frequently Asked Questions Learn more about PE Ratio without NRI →
What does a PE Ratio without NRI of 147.56 mean?
Knight Therapeutics (FRA:04K) has a PE Ratio without NRI of 147.56 as of Jul. 04, 2026. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Knight Therapeutics and its competitors. This is 94% above median its historical median of 76.03. Over the past decade, Knight Therapeutics' PE Ratio without NRI has ranged from 42.79 to 4,025.00. According to the industry distribution chart, Knight Therapeutics ranks #620 out of 654 companies in the Drug Manufacturers industry, placing it in the top 94.8%.
Is Knight Therapeutics' PE Ratio without NRI too high?
Knight Therapeutics' current PE Ratio without NRI of 147.56 is 94% above median its 10-year median of 76.03. Over the past 10 years, this metric has ranged from a low of 42.79 to a high of 4,025.00. The Drug Manufacturers industry median PE Ratio without NRI is 20.87. Knight Therapeutics' value of 147.56 is 607% above this industry median. Based on the distribution chart, Knight Therapeutics ranks #620 out of 654 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Knight Therapeutics has a GF Score™ of 73/100, reflecting its overall financial health beyond just this single metric.
How does Knight Therapeutics' PE Ratio without NRI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Knight Therapeutics ranks #620 out of 654 companies for PE Ratio without NRI. This places Knight Therapeutics in the lower half of its industry. The industry median PE Ratio without NRI is 20.87. Knight Therapeutics' value of 147.56 is 607% above this benchmark. Historically, Knight Therapeutics' own PE Ratio without NRI has ranged from 42.79 to 4,025.00 over the past decade. While the company's 10-year median is 76.03 vs. the industry median of 20.87, Knight Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio without NRI for a Drug Manufacturers company?
The median PE Ratio without NRI among Drug Manufacturers companies is 20.87, based on 654 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio without NRI significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Knight Therapeutics's current PE Ratio without NRI of 147.56 is 607% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio without NRI mean?
A high PE Ratio without NRI can signal that a stock is expensive relative to its fundamentals. P/E without nonrecurring items is the ratio of share price to a company's earnings less one-time charges. View historical data on Knight Therapeutics and its competitors. For the Drug Manufacturers industry, the median PE Ratio without NRI is 20.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Knight Therapeutics's current PE Ratio without NRI is 147.56, which is 94% above median its own 10-year median of 76.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Knight Therapeutics stock overvalued right now?
Knight Therapeutics (FRA:04K) has a current PE Ratio without NRI of 147.56. The stock's GF Value™ is €5.30, compared to a current price of €6.05 — trading 14.2% above its estimated fair value. The current PE Ratio without NRI is 147.56, which is 94% above median its 10-year median of 76.03 and 607% above the Drug Manufacturers industry median of 20.87. Knight Therapeutics' overall GF Score™ is 73/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio without NRI calculated?
PE Ratio without NRI is calculated from a company's financial statements. For Knight Therapeutics (FRA:04K), the current PE Ratio without NRI is 147.56 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Knight Therapeutics (FRA:04K) Overvalued in 2026?

Based on GuruFocus' analysis, Knight Therapeutics stock appears to be overvalued. The current stock price of €6.05 is trading 14.2% above its estimated GF Value™ of €5.30.

Key valuation signals for FRA:04K:

  • PE Ratio without NRI: 147.56 (94% above median its 10-year median of 76.03)
  • GF Value™: €5.30 vs. price of €6.05 (14.2% above fair value)
  • GF Score™: 73/100 with 6 warning signs
  • Industry Position: 607% above the Drug Manufacturers median (#620 of 654)

No single metric tells the full story. See the FRA:04K stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Knight Therapeutics Business Description

Other Exchanges KHTRF:USAGUD:Canada
Address 100 Alexis Nihon Boulevard, Suite 600, Saint-Laurent, QC, CAN, H4M 2P2
Knight Therapeutics Inc is a specialty and generic drug manufacturing company. The company's principal business activity is focused on developing, acquiring, in-licensing, out-licensing, marketing, and commercializing pharmaceuticalproducts. and distributing pharmaceutical products, consumer health products, and medical devices in Canada, Latin America and select international markets. The company finances other life sciences companies across the globe in order to generate interest income, strengthen relationships in the life sciences industry, and to secure product distribution rights. Geographically, the company generates revenue from Brazil, Canada, Colombia, Argentina, Mexico, Rest of LATAM, and Others, with the majority revenue generated from the Brazil region.
73GF Score

Get the complete analysis for FRA:04K

PE Ratio without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.05
Price
€5.30
GF Value